The protective proteins in our bodies aren’t just great for fending off infection—they could also fight the effects of ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

“Maybe generative AI isn't just going to create beautiful cartoons and limericks to entertain ourselves and one another, and ...

In a groundbreaking development that could change the lives of thousands of people with spinal cord injuries, European ...

The adjuvanted RSV prefusion F protein-based vaccine RSVPreF3-AS01E Arexvy was first FDA approved for older adults in May ...

Ovarian cancer cells exploit cell competition by altering Flower protein isoforms in stromal cells, promoting tumor survival ...

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, ...

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

Researchers from Elpiscience Biopharmaceuticals Inc. discussed the discovery and preclinical characterization of a novel NKG2A antibody-IL-2 mutant fusion protein – ES-015.129 – being developed as ...

HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma.

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and ...

Cardinalizumab (Ketanil) is a bi-specific antibody acts as programmed death 1 protein (PD-1) antagonist and CTLA4 antagonist. It is formulated as solution for inravenous route of administration.